Mycophenolate mofetil in treatment of idiopathic stages III-IV membranous nephropathy
نویسندگان
چکیده
منابع مشابه
Mycophenolate Mofetil/Prednisolone Versus Methylprednisolone/Chlorambucil Treatment in Idiopathic Membranous Nephropathy Stage III-IV
Background. In 1984 Ponticelli et al. published the results of a controlled study where patients with idiopathic membranous nephropathy (IMN) and nephrotic syndrome were randomized to receive supportive therapy or to be given a six month therapy with methylprednisolone and chlorambucil alternated every other month, with significantly better outcome in treated patients. Mycophenolate mofetil (MM...
متن کاملMycophenolate mofetil and cyclosporine therapy in membranous nephropathy.
Idiopathic membranous nephropathy (IMN) remains one of the most common causes of the nephrotic syndrome (NS) in adults. Although the natural history is extremely variable, approximately two thirds of the patients will have persistent high-grade proteinuria and/or develop renal failure over a decade of observation. On the other hand, the remaining third of patients will remit spontaneously and p...
متن کاملTreatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study.
BACKGROUND Membranous nephropathy is a common cause of nephrotic syndrome (NS) in adults. Its treatment is still under debate. METHODS We report our experience in a pilot study using initially low doses of steroids and tacrolimus (Tac). After 3 months of treatment, mycophenolate mofetil (MMF) was added if the proteinuria was higher than 1 g/day. RESULTS In accordance with this standard, 21 ...
متن کاملTreatment of idiopathic membranous nephropathy.
Exciting progress recently has been made in our understanding of idiopathic membranous nephropathy, as well as treatment of this disease. Here, we review important advances regarding the pathogenesis of membranous nephropathy. We will also review the current approach to treatment and its limitations and will highlight new therapies that are currently being explored for this disease including Ri...
متن کاملTreatment with rituximab in idiopathic membranous nephropathy
BACKGROUND Rituximab represents a valid therapeutic option to induce remission in patients with primary glomerulonephritis. Despite several studies proving its efficacy in improving outcomes in patients with membranous nephropathy (MN), its role in therapeutic protocols is not yet defined. METHODS We studied 38 patients with idiopathic MN treated with rituximab (in 13 patients as first-line t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nephrology Dialysis Transplantation
سال: 2003
ISSN: 0931-0509,1460-2385
DOI: 10.1093/ndt/gfg113